Biocon Launches Haselmeiers Insulin Pen in India

Zurich, Switzerland, November 22, 2011 Haselmeier has announced that Biocon, one of Asias premier biotechnology companies, has launched INSUPen in India. Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen, for use with Biocons insulin and insulin analogues. The first launch of the INSUPen has taken place with Biocons Basalog and Insugen insulins. The INSUPen is a reusable insulin pen based on Haselmeiers popular i-pen technology. It is designed to be easy to use for the patient and provide accurate and reliable dosing. The INSUPen is available in 3 attractive colors and is currently custom designed for use with both Basalog and Insugen, thus maximizing patient convenience The INSUPen provides diabetic patients an attractive pen with user-friendly features at an affordable cost. Haselmeier is proud to work with Biocon, a premier biotechnology company, on this important program to develop and supply INSUPen and we look forward to a long and successful partnership, said Volker Wirth, Director Business Development & Marketing at Haselmeier. Rakesh Bamzai, President, Marketing at Biocon added: I am confident that INSUPen will be a delight for patients and a value enhancer for all stakeholders. About Haselmeier GmbH Haselmeier is a leading designer and manufacturer of pen and auto-injection systems. The Companys devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. For more information visit: www.haselmeier.com

About Biocon Limited Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocons value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocons robust product offering includes the worlds first Pichia-based recombinant human Insulin, INSUGEN and Indias first indigenously produced monoclonal antibody BIOMAbEGFR(TM).www.biocon.com